Applied Protein Technology Secures Series C Financing to Accelerate Multi-Omics Innovation
Shanghai-based Applied Protein Technology (APTBIO), a pioneer in life science technology services driven by mass...
Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Hinova Pharmaceuticals Receives NMPA Greenlight for HP501 Clinical Trial in Gout Patients
Shanghai-based Hinova Pharmaceuticals Inc. (SHA: 688302) has announced that it has received approval from the...
Junshi Biosciences’ Toripalimab Approved for First-Line RCC Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has received a new indication approval...
Ascletis Pharma Halts ASC42 Phase II Study in Primary Biliary Cholangitis
China-based Ascletis Pharma Inc. (HKG: 1672) has announced its decision to terminate the Phase II...
IASO Biotherapeutics Gains FDA Nod for Fucaso CAR-T Study in Myasthenia Gravis
China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...
Ipsen Secures NMPA Approval for Somatuline in Advanced Neuroendocrine Tumors
Ipsen (EPA: IPN; OTCMKTS: IPSEY), a France-based biopharmaceutical company, has received new indication approval from...
Shanghai Henlius Reports Phase III Success for HLX14 in Osteoporosis Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696), based in China, has announced that its global, multi-center...
Siemens Healthineers and Siemens China Partner with Fudan Hospital Logistic Service on Green Imaging Centers
Germany-based Siemens Healthineers AG, along with its subsidiary Siemens China, has entered into a strategic...
Mabwell Bioscience Receives NMPA Approval for Biosimilar Version of Amgen’s Xgeva
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received market approval...
Walvax Biotechnology’s COVID-19 Variant Vaccine RQ3033 Shows Positive Phase III Results
China-based Walvax Biotechnology Co., Ltd (SHE: 300142) has announced positive results from a Phase III...
Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration
Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource...
Legend Biotech’s Carvykti Secures FDA Approval for Expanded Use in Multiple Myeloma
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced that the US Food and Drug Administration...
Genmab Acquires Profound Bio for $1.8 Billion, Targeting Expanding ADC Pipeline
Denmark-based biotech Genmab A/S (NASDAQ: GMAB) has announced a significant all-cash acquisition of Sino-US biotech...
Boehringer Ingelheim to Shut Down Consanas Rehabilitation Unit in China Amid Disappointing Performance
Boehringer Ingelheim (BI), the Germany-based pharmaceutical firm, is set to close its Consanas Rehabilitation stroke...
European Commission Approves Reblozyl for First-Line Treatment of MDS-Related Anemia
The European Commission (EC) has granted Bristol Myers Squibb (BMS; NYSE: BMY) an indication extension...
Gilead Extends Collaboration with Nurix Therapeutics for Targeted Protein Degradation by Two Years
Gilead Sciences (NASDAQ: GILD) has announced a two-year extension of its 2019 collaboration with Nurix...
RemeGen Plans RMB 2.55 Billion Private Placement to Fund Innovative Drug Development
China-based RemeGen (HKG: 9995) has announced plans to raise RMB 2.55 billion (approximately USD 280.5...
AstraZeneca and Daiichi Sankyo File for FDA Approval of Datopotamab Deruxtecan in Breast Cancer
AstraZeneca (AZ; NASDAQ: AZN), headquartered in the UK, and its Japanese partner Daiichi Sankyo (TYO:...
Sichuan Biokin Secures NMPA Approval for Phase II Study of BL-M07D1 in Advanced Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506), based in China, has announced that it has...